“…To date, there are only a few subunit vaccine platforms capable of producing this level of T cell expansion, one of which is a combination adjuvant stimulating both an innate receptor (such as a TLR) and CD40 (combined innate/CD40). Much like the B cell response, the use of either of these single adjuvants typically produces around 10–50,000 total antigen specific CD8+ T cells [2], a number that is non-protective with respect to T cell responses [13]. In contrast, after a single exposure, the combined innate/CD40 adjuvant can produce a similar number of antigen specific T cells (~1–3 million antigen specific T cells), and in the same time frame (7 days), as the infectious challenge [2, 10, 13, 44, 45].…”